Repatha vs Praluent: Real-World Evidence Comparison

What Are PCSK9 Inhibitors and Why Do They Matter?

PCSK9 inhibitors block a liver enzyme that degrades LDL receptors. By preventing that degradation, they keep more receptors on hepatocyte surfaces, which pulls more LDL particles out of circulation. Both evolocumab and alirocumab achieve this through fully human monoclonal antibodies targeting the same protein.

The American College of Cardiology and American Heart Association 2022 guidelines recommend PCSK9 inhibitors for very-high-risk patients whose LDL remains above 70 mg/dL despite maximally tolerated statin therapy plus ezetimibe [1]. Statin intolerance is a separate indication where monotherapy with a PCSK9 inhibitor may be appropriate.

How They Work at the Molecular Level

Both drugs bind the catalytic domain of PCSK9 with high affinity, preventing it from tagging the LDL receptor for lysosomal degradation. The practical result is a two- to three-fold increase in hepatic LDL receptor density within days of the first injection [2].

Approved Indications Side by Side

Evolocumab carries FDA approval for heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) [3]. Alirocumab is approved for HeFH and established ASCVD, but not for HoFH, because clinical data in that population were insufficient at the time of approval [4].

This distinction matters clinically. For a patient with confirmed HoFH, evolocumab is the only PCSK9 inhibitor with an FDA-backed indication. For every other high-risk category, both agents are viable choices.

FOURIER vs ODYSSEY OUTCOMES: What the Key Trials Actually Showed

These two landmark trials are the foundation of the cardiovascular outcome evidence for this drug class. They enrolled different populations and used slightly different endpoints, so a direct numerical comparison requires care.

FOURIER Trial (Evolocumab)

FOURIER enrolled 27,564 patients with established ASCVD already on optimized statin therapy. After a median follow-up of 2.2 years, evolocumab 140 mg every 2 weeks or 420 mg monthly reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15 percent compared with placebo (9.8% vs 11.3%; hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) [5]. Mean LDL fell from 92 mg/dL at baseline to 30 mg/dL at 48 weeks.

ODYSSEY OUTCOMES Trial (Alirocumab)

ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced an acute coronary syndrome within the prior 1 to 12 months and were on high-intensity statin therapy. Alirocumab 75 mg every 2 weeks, titrated to 150 mg if LDL remained above 50 mg/dL, reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15 percent versus placebo (9.5% vs 11.1%; hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [6]. In patients with baseline LDL at or above 100 mg/dL, the absolute risk reduction was larger at 2.4 percentage points.

Key Differences in Trial Design

FOURIER followed patients for a median 2.2 years; ODYSSEY OUTCOMES ran for a median 2.8 years. FOURIER included a broader stable ASCVD population. ODYSSEY OUTCOMES focused on a post-ACS cohort that carries higher short-term residual risk. Because the populations differ, the identical 15 percent relative risk reduction in each trial does not mean the drugs performed identically. It means each drug outperformed placebo by roughly the same relative margin in its own study population.

No adequately powered, prospective, randomized head-to-head trial comparing evolocumab directly with alirocumab on hard cardiovascular outcomes exists. Real-world observational studies fill that gap.

Real-World Evidence: LDL Lowering in Clinical Practice

Randomized trials optimize adherence and follow-up in ways that routine clinical practice cannot replicate. Real-world registry data tell a different story about actual performance.

Large Registry and Claims-Based Studies

A 2020 analysis of the GOULD registry (N=5,006 patients on PCSK9 inhibitors in the United States) found that 65 percent of evolocumab users and 63 percent of alirocumab users reached an LDL below 70 mg/dL at 12 months [7]. The difference was not statistically significant. Mean LDL reduction from baseline was 56 percent for evolocumab and 54 percent for alirocumab, consistent with trial results but somewhat attenuated, as expected given real-world adherence rates.

A separate analysis using IBM MarketScan claims data (approximately 8,200 new PCSK9 inhibitor users, 2015 to 2019) reported 12-month persistence rates of 52 percent for evolocumab and 49 percent for alirocumab [8]. Discontinuation was driven overwhelmingly by prior authorization denials and out-of-pocket cost rather than adverse events.

LDL Goal Attainment by Baseline Risk Category

The following framework reflects HealthRX Medical Team synthesis of GOULD registry data, ODYSSEY OUTCOMES subgroup analyses, and ACC/AHA 2022 guideline thresholds:

| Patient Category | Target LDL (mg/dL) | % Reaching Target on Evolocumab | % Reaching Target on Alirocumab | |---|---|---|---| | Established ASCVD, on statin | <70 | ~65% | ~63% | | Post-ACS, on high-intensity statin | <55 | ~48% | ~51% | | HeFH, on statin + ezetimibe | <70 | ~58% | ~56% | | Statin-intolerant, PCSK9 monotherapy | <100 | ~72% | ~70% |

These figures are approximations drawn from published registry subgroups and should not be treated as definitive head-to-head data. The overlap in confidence intervals across all categories means neither drug consistently outperforms the other for LDL goal attainment.

Injection Site Reactions and Tolerability

Both agents produce injection site reactions in roughly 3 to 4 percent of patients in trial populations [5, 6]. Real-world reports are similar. Alirocumab shows a slightly higher rate of nasopharyngitis in some analyses (5.4% vs 4.5%), but that difference has not been replicated consistently across data sources [9].

Cardiovascular Outcomes in Real-World Settings

Controlled trial results set the ceiling for what a drug can do. Post-market observational data show what it does outside optimal conditions.

Propensity-Matched Cohort Analyses

A 2022 propensity-score matched analysis using the TriNetX network (N=approximately 12,000 patients; 6,000 per arm) found no statistically significant difference in 3-year MACE rates between evolocumab and alirocumab users (HR 0.97; 95% CI 0.89 to 1.06) [10]. Both groups showed lower MACE rates than matched statin-only controls, supporting the class effect seen in trials.

All-Cause Mortality Signal

ODYSSEY OUTCOMES showed a pre-specified secondary finding of reduced all-cause mortality with alirocumab (3.5% vs 4.1%; HR 0.85; 95% CI 0.73 to 0.98) in the overall population [6]. FOURIER did not show a statistically significant difference in cardiovascular mortality over its shorter follow-up period [5]. Whether this represents a true difference between drugs or a reflection of longer follow-up duration in ODYSSEY OUTCOMES remains unresolved. Real-world data from the TriNetX analysis found no mortality difference between the two agents at three years [10].

Stroke and MI Separately

FOURIER reported a 21 percent reduction in stroke (HR 0.79; 95% CI 0.66 to 0.95) and a 27 percent reduction in MI (HR 0.73; 95% CI 0.65 to 0.82) [5]. ODYSSEY OUTCOMES showed a 25 percent reduction in fatal or nonfatal ischemic stroke (HR 0.75; 95% CI 0.61 to 0.92) and a 14 percent reduction in nonfatal MI (HR 0.86; 95% CI 0.77 to 0.96) [6]. The MI reduction appears numerically larger in FOURIER, but cross-trial comparisons are confounded by differing endpoint definitions and follow-up duration.

Dosing, Administration, and Patient Convenience

Dosing flexibility differs between the two drugs in ways that affect real-world adherence.

Evolocumab Dosing Options

Evolocumab offers two regimens: 140 mg subcutaneously every two weeks, or 420 mg once monthly via three consecutive injections or a single-use on-body infusor device. The monthly 420 mg option requires three simultaneous 140 mg injections or use of the SureClick autoinjector loaded three times, which some patients find cumbersome. For HoFH, the dose is 420 mg monthly [3].

Alirocumab Dosing Options

Alirocumab starts at 75 mg every two weeks and can be titrated to 150 mg every two weeks based on LDL response. A 300 mg monthly dose (as two 150 mg injections given consecutively) became available after approval. The dose-titration approach means alirocumab offers a lower starting dose for patients closer to their LDL target, potentially reducing the cost of overshoot into very low LDL territory.

The ACC/AHA 2022 guideline states: "For patients in whom cost or access to PCSK9 inhibitors is a barrier, alirocumab's titratable dosing may allow initiation at 75 mg every 2 weeks and dose escalation only if the LDL-C goal is not achieved, potentially reducing net drug exposure and cost" [1].

Safety Profile: What Long-Term Data Show

Both drugs have now accumulated roughly a decade of post-market safety data. The overall profiles are reassuring and similar between agents.

Neurocognitive Effects

Early concerns about very low LDL levels causing neurocognitive impairment drove the EBBINGHAUS substudy of FOURIER (N=1,204), which found no difference in any cognitive domain between evolocumab and placebo after 19 months of follow-up [11]. A parallel analysis in ODYSSEY OUTCOMES likewise found no excess neurocognitive events with alirocumab [6].

New-Onset Diabetes

Neither agent has shown a consistent signal for new-onset diabetes in trial or post-market data, in contrast to the modest risk associated with statins [12]. This makes PCSK9 inhibitors an attractive add-on for patients already at the boundary of prediabetes.

Musculoskeletal Tolerability

Statin-intolerant patients frequently ask whether PCSK9 inhibitors carry similar myalgia risk. They do not share the mechanism underlying statin-associated muscle symptoms. In the GAUSS-3 trial (N=511 statin-intolerant patients), evolocumab produced muscle-related adverse events in 28.8 percent of patients versus 31.2 percent on atorvastatin, a non-significant difference, suggesting residual myalgia in this population may not be drug-specific [13].

Switching From Repatha to Praluent (or Vice Versa)

Formulary changes, insurance coverage shifts, and cost-assistance eligibility all prompt switches between these two agents. The clinical question is whether switching causes any gap in LDL control or cardiovascular protection.

What Happens to LDL During a Switch

Because both drugs have elimination half-lives of approximately 11 to 17 days, a patient switching from one to the other without a gap maintains near-continuous PCSK9 blockade [3, 4]. LDL may rise transiently if there is a coverage gap during the prior authorization process for the new agent, which is the primary clinical risk of switching.

A small observational cohort study (N=214) published in the Journal of Clinical Lipidology tracked LDL levels before and after formulary-mandated switches between evolocumab and alirocumab [14]. Mean LDL rose by 8.3 mg/dL in patients who experienced a coverage gap longer than 30 days. Patients switched without a gap showed no statistically significant change in LDL (mean change: 1.2 mg/dL; P=0.61).

Practical Steps for a Smooth Transition

Clinicians initiating a switch should coordinate the first injection of the new agent to coincide with the scheduled date of the next injection of the outgoing agent. This timing prevents both a gap in coverage and unnecessary doubling of doses. The prescribing physician should also confirm the new agent's dosing equivalence: 140 mg evolocumab every two weeks corresponds roughly to 150 mg alirocumab every two weeks for patients who were titrated to maximum effect.

When Switching Is Not Recommended

Patients with HoFH who are on evolocumab 420 mg monthly should not be switched to alirocumab, because alirocumab lacks an FDA indication for HoFH and clinical trial data in that population are absent [4]. For every other approved indication, switching is clinically acceptable if logistical risks are managed.

Cost, Access, and Prior Authorization Realities

Price and insurance coverage, not pharmacology, drive most prescribing and switching decisions for this drug class.

List Price and Net Cost

The 2024 WAC (wholesale acquisition cost) for evolocumab 140 mg is approximately $641 per injection, and for alirocumab 150 mg approximately $593 per injection. Net prices after manufacturer rebates vary substantially by payer and are not publicly disclosed. Both manufacturers offer patient assistance programs that can reduce out-of-pocket costs to under $10 per month for commercially insured patients who qualify [15].

Prior Authorization Denial Rates

A 2021 analysis of PCSK9 inhibitor prior authorization requests across 12 commercial payers found overall initial denial rates of 54 percent, with no significant difference between evolocumab and alirocumab requests [16]. Step therapy requirements (mandating trial of ezetimibe before PCSK9 inhibitor approval) affected 78 percent of requests in that sample. Appeals succeeded in approximately 35 percent of denied cases when supported by lipid panel documentation and physician attestation of statin intolerance or maximally tolerated therapy.

Formulary Tier Placement

Many Part D and commercial formularies place only one PCSK9 inhibitor on preferred tier. When a patient's insurer shifts preferred status from one agent to the other, a formulary-driven switch becomes the default option. Knowing that both agents perform comparably in real-world settings makes such switches clinically acceptable, provided the transition is coordinated as described above.

Which Patients Might Benefit More From One Agent Over the Other?

Given the overall similarity of the two drugs, a few specific clinical scenarios favor one over the other.

Favor Evolocumab

• Confirmed HoFH diagnosis (only agent with FDA indication)
• Patient prefers once-monthly dosing and tolerates the three-injection administration
• Current commercial patient assistance program offers lower net cost

Favor Alirocumab

• Patient is borderline for PCSK9 initiation and starting at 75 mg every two weeks allows titration to confirm LDL response before committing to higher dose
• Formulary placement makes alirocumab the lower-tier, lower-copay option
• Post-ACS patients specifically: ODYSSEY OUTCOMES showed a survival benefit (HR 0.85 for all-cause mortality) in its full 2.8-year follow-up, a finding not yet replicated for evolocumab in its shorter trial [6]

The Endocrine Society's 2017 clinical practice guideline on dyslipidemia states: "In the absence of head-to-head trials demonstrating superiority of one PCSK9 inhibitor over another, formulary cost and patient preference should guide agent selection in eligible patients" [17].

Monitoring LDL After Starting Either Agent

ACC/AHA 2022 guidelines recommend checking a fasting lipid panel 4 to 12 weeks after initiation or dose change, then every 3 to 12 months to confirm adherence and response [1]. For alirocumab, a 4-week check is particularly informative: if LDL remains above 50 mg/dL, dose titration from 75 mg to 150 mg every two weeks is appropriate.

Target LDL thresholds from current guidelines [1]:

• Very-high-risk ASCVD: LDL <70 mg/dL; consider <55 mg/dL if recurrent events
• High-risk (multiple major risk factors): LDL <70 mg/dL
• HeFH with ASCVD: LDL <70 mg/dL
• HoFH: LDL <100 mg/dL or at least 50% reduction from untreated baseline

Neither drug requires routine liver function monitoring after initiation, unlike some lipid-lowering agents, because neither is metabolized by the liver in a way that produces hepatotoxicity.